(Q38666253)

5 September 2017

1 reference

title

The future of immune checkpoint cancer therapy after PD-1 and CTLA-4. (English)

1 reference

5 September 2017

Andrew W Hahn

1

1 reference

5 September 2017

David M Gill

series ordinal

2

1 reference

5 September 2017

Sumanta K Pal

series ordinal

3

1 reference

5 September 2017

Neeraj Agarwal

series ordinal

4

1 reference

5 September 2017

language of work or name

1 reference

1 June 2017

1 reference

5 September 2017

1 reference

5 September 2017

volume

9

1 reference

5 September 2017

issue

8

1 reference

5 September 2017

page(s)

681-692

1 reference

Cancer immunoediting: from immunosurveillance to tumor escape

5 September 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

Expression of tumour-specific antigens underlies cancer immunoediting

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

Effector memory T cells, early metastasis, and survival in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

The B7 family and cancer therapy: costimulation and coinhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

The CD28 ligand B7/BB1 provides costimulatory signal for alloactivation of CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

Cloning of B7-2: a CTLA-4 Counter-Receptor That Costimulates Human T Cell Proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

PD-L2 is a second ligand for PD-1 and inhibits T cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

B7x: a widely expressed B7 family member that inhibits T cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

TNF/TNFR family members in costimulation of T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

PD-1 and its ligands in tolerance and immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

Nivolumab in previously untreated melanoma without BRAF mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

Immunostimulatory monoclonal antibodies for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

Immunotherapy: Beyond Anti-PD-1 and Anti-PD-L1 Therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

Co-inhibition of CD73 and A2AR Adenosine Signaling Improves Anti-tumor Immune Responses

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

Extracellular adenosine triphosphate and adenosine in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

Adenosine receptors in regulation of dendritic cell differentiation and function

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

Targeting cancer-derived adenosine: new therapeutic approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

Systemic oxygenation weakens the hypoxia and hypoxia inducible factor 1α-dependent and extracellular adenosine-mediated tumor protection

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

Adenosine Receptor 2A Blockade Increases the Efficacy of Anti-PD-1 through Enhanced Antitumor T-cell Responses

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

Expression of lymphocyte activation gene 3 (LAG-3) on B cells is induced by T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

Novel antibodies targeting immune regulatory checkpoints for cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

Phenotypic analysis of the murine CD4-related glycoprotein, CD223 (LAG-3).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

Immune checkpoint blockade: a common denominator approach to cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+ T cell dysfunction in melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

T-cell immunoglobulin mucin 3 blockade drives an antitumor immune response in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

B7-H3 is a new cancer-specific endothelial marker in clear cell renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

The coexpression and clinical significance of costimulatory molecules B7-H1, B7-H3, and B7-H4 in human pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

B7-H3 expression in colorectal cancer: associations with clinicopathological parameters and patient outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

B7-H1 and B7-H3 are independent predictors of poor prognosis in patients with non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

Association of T-cell co-regulatory protein expression with clinical outcomes following radical cystectomy for urothelial carcinoma of the bladder.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

A new member of the tumor necrosis factor/nerve growth factor receptor family inhibits T cell receptor-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

Identification of a new member of the tumor necrosis factor family and its receptor, a human ortholog of mouse GITR

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

Dual Roles for Regulatory T-cell Depletion and Costimulatory Signaling in Agonistic GITR Targeting for Tumor Immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

Expression and function of 4-1BB during CD4 versus CD8 T cell responses in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

Cross-linking of 4-1BB activates TCR-signaling pathways in CD8+ T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

Exposure of a distinct PDCA-1+ (CD317) B cell population to agonistic anti-4-1BB (CD137) inhibits T and B cell responses both in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

4-1BB promotes the survival of CD8+ T lymphocytes by increasing expression of Bcl-xL and Bfl-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

Temporal segregation of 4-1BB versus CD28-mediated costimulation: 4-1BB ligand influences T cell numbers late in the primary response and regulates the size of the T cell memory response following influenza infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

The combination of 4-1BBL and CD40L strongly enhances the capacity of dendritic cells to stimulate HIV-specific T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

4-1BB (CD137) differentially regulates murine in vivo protein- and polysaccharide-specific immunoglobulin isotype responses to Streptococcus pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

Combinatorial PD-1 blockade and CD137 activation has therapeutic efficacy in murine cancer models and synergizes with cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

Functional dichotomy between OX40 and 4-1BB in modulating effector CD8 T cell responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

A Novel Murine GITR Ligand Fusion Protein Induces Antitumor Activity as a Monotherapy That Is Further Enhanced in Combination with an OX40 Agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

OX40 is a potent immune-stimulating target in late-stage cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

Targeting the T-cell co-stimulatory CD27/CD70 pathway in cancer immunotherapy: rationale and potential

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

Expression of the murine CD27 ligand CD70 in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

Molecular and biological characterization of a ligand for CD27 defines a new family of cytokines with homology to tumor necrosis factor

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

A subset of dendritic cells induces CD4+ T cells to produce IFN-gamma by an IL-12-independent but CD70-dependent mechanism in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

During viral infection of the respiratory tract, CD27, 4-1BB, and OX40 collectively determine formation of CD8+ memory T cells and their capacity for secondary expansion

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

CD70-driven costimulation induces survival or Fas-mediated apoptosis of T cells depending on antigenic load.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

Control of Established Melanoma by CD27 Stimulation Is Associated With Enhanced Effector Function and Persistence, and Reduced PD-1 Expression of Tumor Infiltrating CD8+ T Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

Anti-tumor effects of depleting and non-depleting anti-CD27 monoclonal antibodies in immune-competent mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

Sunitinib depletes myeloid-derived suppressor cells and synergizes with a cancer vaccine to enhance antigen-specific immune responses and tumor eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

Radiotherapy and immune checkpoint blockades: a snapshot in 2016.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

Current clinical trials testing the combination of immunotherapy with radiotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2017-0024

21 January 2018

Identifiers

DOI

10.2217/IMT-2017-0024

1 reference

release_tisisrq7tnenrilf2bhw42nwzi

5 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/tisisrq7tnenrilf2bhw42nwzi

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference